James J Clark1, Dominic Dwyer2, Nina Pinwill2, Peter Clark2, Peter Johnson3, Allan Hackshaw4. 1. Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: james.clark12@nhs.net. 2. Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK. 3. Medical Directorate, NHS England & NHS Improvement, Skipton House, London, UK; Cancer Research UK Research Centre, University of Southampton, Southampton, UK. 4. Cancer Research UK and UCL Cancer Trials Centre, Cancer Institute, University College London, London, UK.
Abstract
BACKGROUND: Cancer services worldwide had to adapt in response to the COVID-19 pandemic to minimise risk to patients and staff. We aimed to assess the national impact of COVID-19 on the prescribing of systemic anticancer treatment in England, immediately after lockdown and after the introduction of new treatments to reduce patient risk. METHODS: We did a retrospective analysis using data from a central National Health Service England web database mandated for clinicians to register intention to start all new systemic anticancer treatments approved for use in England since 2016. We analysed the monthly number of treatment registrations in April, 2020, after the implementation of societal lockdown on March 23, 2020, and after implementation of treatment options to reduce patient risk such as oral or less immunosuppressive drugs, in May and June, 2020. We compared the number of registrations in April-June, 2020, with the mean number of registrations and SD during the previous 6 months of unaffected cancer care (September, 2019, to February, 2020). We calculated the percentage change and absolute difference in SD units for the number of registrations overall, by tumour type, and by type and line of therapy. FINDINGS: In April, 2020, 2969 registrations were recorded, representing 1417 fewer registrations than in the control period (monthly mean 4386; 32% reduction, absolute difference 4·2 SDs, p<0·0001). In May, 2020, total registrations increased to 3950, representing a 10% reduction compared with the control period (absolute difference 1·3 SDs, p<0·0001). In June, 2020, 5022 registrations were recorded, representing a 15% increase compared with the control period (absolute difference 1·9 SDs; p<0·0001]). INTERPRETATION: After the onset of the COVID-19 pandemic, there was a reduction in systemic anticancer treatment initiation in England. However, following introduction of treatment options to reduce patient risk, registrations began to increase in May, 2020, and reached higher numbers than the pre-pandemic mean in June, 2020, when other clinical and societal risk mitigation factors (such as telephone consultations, facemasks and physical distancing) are likely to have contributed. However, outcomes of providing less treatment or delaying treatment initiation, particularly for advanced cancers and neoadjuvant therapies, require continued assessment. FUNDING: None.
BACKGROUND:Cancer services worldwide had to adapt in response to the COVID-19 pandemic to minimise risk to patients and staff. We aimed to assess the national impact of COVID-19 on the prescribing of systemic anticancer treatment in England, immediately after lockdown and after the introduction of new treatments to reduce patient risk. METHODS: We did a retrospective analysis using data from a central National Health Service England web database mandated for clinicians to register intention to start all new systemic anticancer treatments approved for use in England since 2016. We analysed the monthly number of treatment registrations in April, 2020, after the implementation of societal lockdown on March 23, 2020, and after implementation of treatment options to reduce patient risk such as oral or less immunosuppressive drugs, in May and June, 2020. We compared the number of registrations in April-June, 2020, with the mean number of registrations and SD during the previous 6 months of unaffected cancer care (September, 2019, to February, 2020). We calculated the percentage change and absolute difference in SD units for the number of registrations overall, by tumour type, and by type and line of therapy. FINDINGS: In April, 2020, 2969 registrations were recorded, representing 1417 fewer registrations than in the control period (monthly mean 4386; 32% reduction, absolute difference 4·2 SDs, p<0·0001). In May, 2020, total registrations increased to 3950, representing a 10% reduction compared with the control period (absolute difference 1·3 SDs, p<0·0001). In June, 2020, 5022 registrations were recorded, representing a 15% increase compared with the control period (absolute difference 1·9 SDs; p<0·0001]). INTERPRETATION: After the onset of the COVID-19 pandemic, there was a reduction in systemic anticancer treatment initiation in England. However, following introduction of treatment options to reduce patient risk, registrations began to increase in May, 2020, and reached higher numbers than the pre-pandemic mean in June, 2020, when other clinical and societal risk mitigation factors (such as telephone consultations, facemasks and physical distancing) are likely to have contributed. However, outcomes of providing less treatment or delaying treatment initiation, particularly for advanced cancers and neoadjuvant therapies, require continued assessment. FUNDING: None.
Authors: Sven Voigtländer; Amir Hakimhashemi; Elisabeth C Inwald; Olaf Ortmann; Michael Gerken; Stefanie J Klug; Monika Klinkhammer-Schalke; Martin Meyer; Jacqueline Müller-Nordhorn Journal: Dtsch Arztebl Int Date: 2021-10-01 Impact factor: 5.594
Authors: Olga Lyudovyk; Justin Y Kim; David Qualls; Madeline A Hwee; Ya-Hui Lin; Sawsan R Boutemine; Yuval Elhanati; Alexander Solovyov; Melanie Douglas; Eunise Chen; N Esther Babady; Lakshmi Ramanathan; Pallavi Vedantam; Chaitanya Bandlamudi; Sigrid Gouma; Philip Wong; Scott E Hensley; Benjamin Greenbaum; Alexander C Huang; Santosha A Vardhana Journal: Cancer Cell Date: 2022-05-30 Impact factor: 38.585
Authors: Jason K Gurney; Elinor Millar; Alex Dunn; Ruth Pirie; Michelle Mako; John Manderson; Claire Hardie; Chris G C A Jackson; Richard North; Myra Ruka; Nina Scott; Diana Sarfati Journal: Lancet Reg Health West Pac Date: 2021-03-22
Authors: David J Pinato; Lorenza Scotti; Alessandra Gennari; Emeline Colomba-Blameble; Saoirse Dolly; Angela Loizidou; John Chester; Uma Mukherjee; Alberto Zambelli; Juan Aguilar-Company; Mark Bower; Myria Galazi; Ramon Salazar; Alexia Bertuzzi; Joan Brunet; Ricard Mesia; Ailsa Sita-Lumsden; Johann Colomba; Fanny Pommeret; Elia Seguí; Federica Biello; Daniele Generali; Salvatore Grisanti; Gianpiero Rizzo; Michela Libertini; Charlotte Moss; Joanne S Evans; Beth Russell; Rachel Wuerstlein; Bruno Vincenzi; Rossella Bertulli; Diego Ottaviani; Raquel Liñan; Andrea Marrari; M C Carmona-García; Christopher C T Sng; Carlo Tondini; Oriol Mirallas; Valeria Tovazzi; Vittoria Fotia; Claudia A Cruz; Nadia Saoudi-Gonzalez; Eudald Felip; Ariadna R Lloveras; Alvin J X Lee; Thomas Newsom-Davis; Rachel Sharkey; Chris Chung; David García-Illescas; Roxana Reyes; Yien N Sophia Wong; Daniela Ferrante; Javier Marco-Hernández; Isabel Ruiz-Camps; Gianluca Gaidano; Andrea Patriarca; Anna Sureda; Clara Martinez-Vila; Ana Sanchez de Torre; Lorenza Rimassa; Lorenzo Chiudinelli; Michela Franchi; Marco Krengli; Armando Santoro; Aleix Prat; Josep Tabernero; Mieke V Hemelrijck; Nikolaos Diamantis; Alessio Cortellini Journal: Eur J Cancer Date: 2021-04-06 Impact factor: 9.162
Authors: David J Pinato; Josep Tabernero; Mark Bower; Lorenza Scotti; Meera Patel; Emeline Colomba; Saoirse Dolly; Angela Loizidou; John Chester; Uma Mukherjee; Alberto Zambelli; Alessia Dalla Pria; Juan Aguilar-Company; Diego Ottaviani; Amani Chowdhury; Eve Merry; Ramon Salazar; Alexia Bertuzzi; Joan Brunet; Matteo Lambertini; Marco Tagliamento; Anna Pous; Ailsa Sita-Lumsden; Krishnie Srikandarajah; Johann Colomba; Fanny Pommeret; Elia Seguí; Daniele Generali; Salvatore Grisanti; Paolo Pedrazzoli; Gianpiero Rizzo; Michela Libertini; Charlotte Moss; Joanne S Evans; Beth Russell; Nadia Harbeck; Bruno Vincenzi; Federica Biello; Rossella Bertulli; Raquel Liñan; Sabrina Rossi; Maria Carmen Carmona-García; Carlo Tondini; Laura Fox; Alice Baggi; Vittoria Fotia; Alessandro Parisi; Giampero Porzio; Maristella Saponara; Claudia Andrea Cruz; David García-Illescas; Eudald Felip; Ariadna Roqué Lloveras; Rachel Sharkey; Elisa Roldán; Roxana Reyes; Irina Earnshaw; Daniela Ferrante; Javier Marco-Hernández; Isabel Ruiz-Camps; Gianluca Gaidano; Andrea Patriarca; Riccardo Bruna; Anna Sureda; Clara Martinez-Vila; Ana Sanchez de Torre; Luca Cantini; Marco Filetti; Lorenza Rimassa; Lorenzo Chiudinelli; Michela Franchi; Marco Krengli; Armando Santoro; Aleix Prat; Mieke Van Hemelrijck; Nikolaos Diamantis; Thomas Newsom-Davis; Alessandra Gennari; Alessio Cortellini Journal: Lancet Oncol Date: 2021-11-03 Impact factor: 41.316